Full Year 2023 Investor Presentation

12 Investor presentation Full year 2023 R&D milestones Clinical milestones¹ Q4 2023 H1 2024 Diabetes care Obesity care Project Icodec IcoSema FLOW kidney outcomes trial STRIDE SOUL CVOT OW GLP-1/GIP OM GLP-1/GIP SELECT STEP HFPEF STEP OA Cagrisema ✓ Phase 3 results Phase 3 results Phase 3 results Phase 3 results Novo NordiskⓇ Regulatory milestones¹ H2 2024 EU/JP/CN/US decision Phase 3 results Phase 3 results Phase 1 results ✓ Phase 1 initiation US decision EU/US submission EU/CN decision Rare Disease Oral Amycretin Mim8 ✓ Phase 1 results Phase 3 results CV & Emerging Therapy Areas VAP-1i Phase 1 initiation Phase 3 results 1Expected to be published in the given quarter or in the subsequent quarterly company announcement CVOT: Cardiovascular Outcomes Trial; CV: Cardiovascular; CN: China; EU: European Union; GIP: Glucacose-dependent insulinotropic polypeptide; HFPEF: Heart failure with preserved ejection fraction; JP: Japan; OA: Osteoarthritis; OW: Once-weekly; OM: Once- monthly; T2D: Type 2 Diabetes; US: United States; VAP-1i: Vascular adhesion protein-1 selective inhibitor

View entire presentation